Pharmaceutical Chemistry Journal
9,10-Anthraquinone Dithiocarbamates as Potential Pharmaceutical Substances with Pleiotropic Actions: Computerized Prediction of Biological Activity and Experimental Validation
M. V. Stasevich
V. I. Zvarich
V. P. Novikov
S. D. Zagorodnyaya
O. Yu. Povnitsa
M. A. Chaika
M. V. Nesterkina
I. A. Kravchenko
D. S. Druzhilovskii
V. V. Poroikov
The pleiotropic pharmacological actions of 9,10-anthraquinone dithiocarbamates were studied. The Way2Drug web portal was used to establish that cytotoxic, antiviral, and anticonvulsant actions were predicted for the study molecules, along with moderate toxicity. In vitro experimental studies showed that all study compounds had cytotoxic effects on tumor cell lines Hep-2, CHO, HeLa, Raji, BL, and B95-8. The high levels of cytotoxicity against cell lines Raji and B95-8 seen with derivatives II, IV, VI, and X was evidence of direct actions on Epstein-Barr virus (EBV). Along with the cytotoxic action, dithiocarbamates V, VIII, and IX showed antiviral effects against herpes virus HSV-2. Compounds VI and X, which had cytotoxic and antiviral actions, produced anticonvulsant effects 3 and 6 h after administration, while dithiocarbamate III, which had cytotoxic activity, retained its antiviral effect 24 h after administration. Dithiocarbamates with pleiotropic actions were moderately toxic (LD50 > 1000 mg/ml, mice, p.o.). Interactions between the structures and the three types of biological activity studied experimentally were assessed.
9,10-anthraquinone dithiocarbamates computer prediction Way2Drug cytotoxic activity antiviral activity anticonvulsant activity
Translated from Khimiko-Farmatsevticheskii Zhurnal, Vol. 53, No. 11, pp. 25 – 33, November, 2019.
V. T. DeVita, T. S. Lawrence, and S. A. Rosenberg, Cancer: Principles and Practice of Oncology, Wolters Kluwer Lippincott Williams & Wilkins, Philadelphia (2011).Google Scholar
P. De Paoli and A. Carbone, Int. J. Cancer, 133(7), 1517 – 1529 (2013).CrossRefGoogle Scholar
J. L. Kutok and F. Wang, Annu. Rev Pathol., No. 1, 375 – 404 (2006).Google Scholar
J. Jalouli, M. M. Jalouli, D. Sapkota, et al., Anticancer Res., 32(2), 571 – 580 (2012).PubMedGoogle Scholar
C. P. Benit and CJ. Vecht, Neuro-Oncology Practice, 3, No. 4, 245 – 260 (2016).Google Scholar
H. Brotz-Oesterhelt and N. A. Brunner, Curr. Opin. Pharmacol., 8(5), 564 – 573 (2008).CrossRefGoogle Scholar
A. L. Hopkins, G. R. Bickerton, I. M. Carruthers, et al., Cur. Top. Med. Chem., 11(10), 1292 – 1300 (2011).CrossRefGoogle Scholar
J. U. Peters, J. Med. Chem., 56(22), 8955 – 8971 (2013).Google Scholar
G. Housman, S. Byler, S. Heerboth, et al., Cancers,6, 3, 1769 – 1792 (2014).CrossRefGoogle Scholar
H. Zahreddine and K. L. Borden, Front. Pharmacol., 4, 28 (2013).CrossRefGoogle Scholar
B. Deslouches and Y. P. Di, Oncotarget, 8(28), 46635 – 46651 (2017).CrossRefGoogle Scholar
V. W. C. Soo, B. W. Kwan, H. Quezada, et al. Curr. Top. Med. Chem., 17(10), 1157 – 1176 (2017).CrossRefGoogle Scholar
M. Micozzi, Fundamentals of Complementary, Alternative, and Integrative Medicine, Elsevier, Riverport Lane (2018).Google Scholar
A. Q. Acton, Anthraquinones — Advances in Research and Application, Scholarly Editions, Atlanta (2013).Google Scholar
V. I. Zvarich, M. V. Stasevich, O. V. Stan'ko, et al., Pharm. Chem. J., 48(9), 584 – 588 (2014).CrossRefGoogle Scholar
M. Stasevych, V. Zvarych, V. Lunin, et al., Indian J. Pharm. Sci., 77(5), 634 – 637 (2015).CrossRefGoogle Scholar
M. Stasevych, V. Zvarych, V. Lunin, et al., Monatsh. Chem., 149(6), 1111 – 1119 (2018).CrossRefGoogle Scholar
E. M. Malik and C. E. Muller, Med. Res. Rev., 36(4), 705 – 748 (2016).CrossRefGoogle Scholar
L. M. L. Nollet and J. A. Gutierrez-Uribe, Phenolic Compounds in Food. Characterization and Analysis, CRC Press, Boca Raton (2018).Google Scholar
A. S. Tikhomirov, A. A. Shtil, and A. E. Shchekotikhin, Recent Pat. Anti-Cancer Drug Discov., 13, 159 – 183 (2018).CrossRefGoogle Scholar
Clarivate Analytics Integrity, 2018; http: //integrity.Thomson-Pharma.com (accessed June 23, 2018).
V. Zvarych, M. Stasevych, V. Lunin, et al., Monatsh. Chem., 147(12), 2093 – 2101 (2016).CrossRefGoogle Scholar
T. I. Halenova, I. V. Nikolaeva, M. V. Stasevych, et al., Res. J. Pharm. Biol. Chem. Sci., 8, 1626 – 1632 (2017).Google Scholar
M. Stasevych, V. Zvarych, V. Lunin., et al., SAR QSAR Environ. Res., 28(5), 355 – 366 (2017).CrossRefGoogle Scholar
D. S. Druzhilovskiy, A. V. Rudik, D. A. Filimonov, et al., Rus. Chem. Bull.,66(10), 1832 – 1841 (2017).CrossRefGoogle Scholar
D. A. Filimonov, D. S. Druzhilovskiy, A. A. Lagunin, et al., Biomed. Chem. Res. Meth., 1, e00004 (2018).CrossRefGoogle Scholar
A. A. Lagunin, V. I. Dubovskaja, A. V. Rudik, et al., PLOS One, 13, e0191838 (2018).CrossRefGoogle Scholar
A. Lagunin, A. Zakharov, D. Filimonov, et al., Mol. Inf.,30(2 – 3), 241 – 250 (2011).CrossRefGoogle Scholar
T. Mosmann, Immunol. J. Meth., 65(1 – 2), 55 – 63 (1983).CrossRefGoogle Scholar
M. Ahmed, Pharmacol. Pharmacy, 6, 185 – 189 (2015).CrossRefGoogle Scholar
J. Švarc-Gajiæ, General Toxicology, Nova Science Publishers Inc., New York (2010).Google Scholar
S. M. Ivanov, A. A. Lagunin D. A. Filimonov, et al., Pharm. Chem. J., 52(8), 758 – 762 (2018).CrossRefGoogle Scholar
R. K. P. Tripathi and S. R. Ayyannan, Med. Chem. Res., 27(3), 709 – 725 (2018).CrossRefGoogle Scholar
V. V. Knyazev, V. S. Rogovskii, E. D. Sveshnikova, et al., Pharm. Chem. J., 52(3), 205 – 208 (2018).CrossRefGoogle Scholar
A. Lagunin, A. Stepanchikova, D. Filimonov, et al., Bioinformatics, 16(8), 747 – 748 (2000).CrossRefGoogle Scholar
PASS Online, 2019; http: //www.way2drug.com/PASSOnline/index.php (accessed July 15, 2019).
K. Anusevicius, V. Mickevicius, M. Stasevych, et al., Res. Chem. Intermed.,41(10), 7517 – 7540 (2015).CrossRefGoogle Scholar
M. V. Nesterkina and I. A. Kravchenko, Chem. Nat. Compd.,52(2), 237 – 239 (2016).CrossRefGoogle Scholar
Clarivate Analytics Integrity (2019); https://integrity.clarivate.com/(accessed July 15, 2019).
Y. C. Martin, J. L. Kofron, and L. M. Traphagen, J. Med. Chem., 45(19), 4350 – 4358 (2002).CrossRefGoogle Scholar
1.Lvov Polytechnic National UniversityLvovUkraine
2.D. K. Zabolotnyi Institute of Microbiology and Virology, Ukrainian National Academy of SciencesKievUkraine
3.Odessa National Polytechnic UniversityOdessaUkraine
4.V. N. Orekhovich Science Research Institute of Biomedical ChemistryMoscowRussia
Stasevich, M.V., Zvarich, V.I., Novikov, V.P. et al. Pharm Chem J (2020). https://doi.org/10.1007/s11094-020-02098-x
Received 27 February 2019
DOI https://doi.org/10.1007/s11094-020-02098-x
Print ISSN 0091-150X